Filter

11 - 20 of 62 Results

  • SUD Treatment in Medicaid: Variation by Service Type, Demographics, States and Spending

    Issue Brief

    Substance use disorders contribute to a growing number of deaths, yet they often go undiagnosed and untreated. While nearly three-quarters of Medicaid enrollees with a diagnosed substance use disorder utilized some type of treatment service in 2020, medication treatment rates varied widely, being much lower for alcohol use disorder than opioid use disorder, and lower among Black enrollees and youth compared to their counterparts. Treatment rates varied considerably across states and average Medicaid spending for…

  • A Look at Substance Use and Mental Health Treatment Facilities Across the U.S.

    Issue Brief

    This brief uses 2022 data from the National Substance Use and Mental Health Services Survey (N-SUMHSS), an annual survey sent to all substance use and mental health treatment facilities to assess the supply and characteristics of these facilities at a national and state level. Despite the escalation of mental health needs and the increasing and evolving opioid epidemic, accessing treatment continues to be difficult--as indicated by consumer surveys and national data. Factors like the decline…

  • Drugs Used for Weight Loss Could Cost Americans Much More Than People in Peer Countries

    News Release

    In addition to having the highest obesity rates, the U.S is currently facing significantly higher prices for several major drugs used for weight loss and other health needs, according to a new KFF analysis of the list prices for semaglutide and tirzepatide drugs. Ozempic, which has been approved in the U.S. for diabetes, is more than five times as expensive in the U.S. ($936) as in Japan ($169), which has the second highest list price.…

  • How Do Prices of Drugs for Weight Loss in the U.S. Compare to Peer Nations’ Prices?

    Issue Brief

    A class of drugs initially approved for diabetes treatment has captured the public’s and policymakers’ attention as interest in their off-label use for weight loss rises. The weight-loss benefits of these drugs have led to their prescribed use for obesity or overweight treatment. A new analysis compares list prices for semaglutide—including Ozempic, which has been approved in the U.S. for diabetes, and Wegovy, which has the same active ingredient and has been approved for weight…

  • KFF Tracking Poll July 2023: Substance Use Crisis And Accessing Treatment

    Poll Finding

    In the midst of an opioid epidemic in the United States, two-thirds of adults say either they or a family member have been impacted by drug or alcohol addiction. Three in ten say they or their family were addicted to prescription or illegal opioids. This survey explores treatments received by those who battled addiction, impacts of addiction, and support for policies aimed at reducing drug overdoses.

  • Mental Health and Substance Use State Fact Sheets

    Feature

    This analysis and series of state fact sheets examine data looking at mental health and substance use disorder across states and capacity to meet residents’ during the COVID-19 pandemic.